These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25555272)

  • 1. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials.
    Bulluck H; Kwok CS; Ryding AD; Loke YK
    Int J Cardiol; 2015 Feb; 181():331-9. PubMed ID: 25555272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
    Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of an abbreviated duration of dual antiplatelet therapy (≤6 months) following second-generation drug-eluting stents for coronary artery disease: A systematic review and meta-analysis of randomized trials.
    Ziada KM; Abdel-Latif AK; Charnigo R; Moliterno DJ
    Catheter Cardiovasc Interv; 2016 Mar; 87(4):722-732. PubMed ID: 26309050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials.
    Verdoia M; Kedhi E; Suryapranata H; Frati G; Biondi-Zoccai G; De Luca G
    J Thromb Thrombolysis; 2020 Aug; 50(2):337-354. PubMed ID: 31919736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The optimal discontinuation of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention with drug-eluting stents: A meta-analysis of randomized trials.
    Wang W; Liu J; Fang J; Liu Y; An T; Zou M; Cheng G
    Int J Cardiol; 2017 May; 235():73-86. PubMed ID: 28284499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    J Am Coll Cardiol; 2016 Sep; 68(10):1116-39. PubMed ID: 27036919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
    ; Bittl JA; Baber U; Bradley SM; Wijeysundera DN
    Circulation; 2016 Sep; 134(10):e156-78. PubMed ID: 27026019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Shorter (≤6 months) versus longer (≥12 months) duration dual antiplatelet therapy after drug eluting stents: a meta-analysis of randomized clinical trials.
    Pandit A; Giri S; Hakim FA; Fortuin FD
    Catheter Cardiovasc Interv; 2015 Jan; 85(1):34-40. PubMed ID: 24753084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal Duration of Dual Antiplatelet Therapy after Drug-Eluting Stents: Meta-Analysis of Randomized Trials.
    Abo-Salem E; Alsidawi S; Jamali H; Effat M; Helmy T
    Cardiovasc Ther; 2015 Oct; 33(5):253-63. PubMed ID: 26010419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents.
    Kandzari DE; Barker CS; Leon MB; Mauri L; Wijns W; Fajadet J; Mehran R
    JACC Cardiovasc Interv; 2011 Oct; 4(10):1119-28. PubMed ID: 22017938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Duration of dual antiplatelet therapy after various drug-eluting stent implantation.
    Sharma A; Sharma SK; Vallakati A; Garg A; Lavie CJ; Mukherjee D; Marmur JD
    Int J Cardiol; 2016 Jul; 215():157-66. PubMed ID: 27116326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal Duration of Dual Antiplatelet Therapy After DES Implantation: A Meta-Analysis of 11 Randomized Trials.
    Verdoia M; Schaffer A; Barbieri L; Montalescot G; Collet JP; Colombo A; Suryapranata H; De Luca G
    Angiology; 2016 Mar; 67(3):224-38. PubMed ID: 26069031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis.
    Yin SH; Xu P; Wang B; Lu Y; Wu QY; Zhou ML; Wu JR; Cai JJ; Sun X; Yuan H
    BMJ; 2019 Jun; 365():l2222. PubMed ID: 31253632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The optimal duration of dual antiplatelet therapy in patients receiving percutaneous coronary intervention with drug-eluting stents.
    Sheyin O; Perez X; Pierre-Louis B; Kurian D
    Cardiol J; 2016; 23(3):307-16. PubMed ID: 26711462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-Analysis of the Duration of Dual Antiplatelet Therapy in Patients Treated With Second-Generation Drug-Eluting Stents.
    D'Ascenzo F; Moretti C; Bianco M; Bernardi A; Taha S; Cerrato E; Omedè P; Montefusco A; Frangieh AH; Lee CW; Campo G; Chieffo A; Quadri G; Pavani M; Zoccai GB; Gaita F; Park SJ; Colombo A; Templin C; Lüscher TF; Stone GW
    Am J Cardiol; 2016 Jun; 117(11):1714-23. PubMed ID: 27134057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short Duration vs Standard Duration of Dual-Antiplatelet Therapy After Percutaneous Coronary Intervention With Second-Generation Drug-Eluting Stents - A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials.
    Wassef AW; Khafaji H; Syed I; Yan AT; Udell JA; Goodman SG; Cheema AN; Bagai A
    J Invasive Cardiol; 2016 Dec; 28(12):E203-E210. PubMed ID: 27630146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials.
    Cassese S; Byrne RA; Tada T; King LA; Kastrati A
    Eur Heart J; 2012 Dec; 33(24):3078-87. PubMed ID: 23091199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients.
    Chong B; Goh RSJ; Kong G; Sim FRE; Ng CH; Teo XYV; Quek JX; Lim O; Chin YH; Chan SP; Chan MY; Tan HC; Chew NWS; Loh PH
    J Thromb Thrombolysis; 2022 Apr; 53(3):671-682. PubMed ID: 34981305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: Meta-analysis of randomized controlled trials.
    Fei Y; Tsoi MF; Cheung TT; Cheung BM
    Int J Cardiol; 2016 Oct; 220():895-900. PubMed ID: 27400191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of dual antiplatelet therapy after drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials.
    Giustino G; Baber U; Sartori S; Mehran R; Mastoris I; Kini AS; Sharma SK; Pocock SJ; Dangas GD
    J Am Coll Cardiol; 2015 Apr; 65(13):1298-1310. PubMed ID: 25681754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.